TherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXY (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe Dyspareunia, a Symptom

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to TherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXY (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe Dyspareunia, a Symptom

TherapeuticsMD (TXMD) PT Raised to $12 at Oppenheimer Following FDA Approval

May 30, 2018 12:26 PM EDT

Oppenheimer raised its price target on TherapeuticsMD (NASDAQ: TXMD) to $12.00 (from $10.00) while maintaining a Outperform rating.

Analyst Jay Olson commented, "TXMD announced FDA approval of Imvexxy (estradiol vaginal inserts) with a label supporting what we view as the best-in-class profile based on safety,... More